Distinct Senescent Β-Cell Senotypes Differentially Drive Islet Aging And Dysfunction

Researchers have discovered that aging pancreatic beta cells, which are vital for regulating blood sugar, develop into two distinct types of senescent cells one that is harmful and contributes to diabetes, and another that maintains its function and is less detrimental.

As we age, our bodies undergo many changes, and sometimes, cells stop dividing but remain active, a state known as cellular senescence. These “senescent cells” can accumulate and contribute to age-related diseases by releasing inflammatory signals. In the pancreas, specialized cells called beta cells are responsible for producing insulin, a hormone crucial for controlling blood sugar levels. When beta cells age and become dysfunctional, it can lead to conditions like type 2 diabetes.

A recent study sheds new light on how beta cells age, revealing that not all senescent beta cells are the same. Researchers found two distinct types of these aging cells within the human pancreas, each with a different impact on the organ’s health and function.

One type of senescent beta cell was found to be particularly problematic. These cells lose their ability to produce insulin effectively and actively promote inflammation within the pancreas. This inflammatory environment can further damage the surrounding tissue and worsen the decline in pancreatic function, contributing to the development and progression of type 2 diabetes.

In contrast, the second type of senescent beta cell appears to be more benign. While these cells have also stopped dividing, they largely retain their ability to produce insulin and exhibit much lower levels of inflammatory signaling. This suggests that some forms of cellular aging in the pancreas might be less harmful or even play a protective role.

This discovery of different “senotypes” – distinct types of senescent cells – is a significant step forward. By understanding these varied cellular aging programs, scientists can work towards developing more targeted treatments for age-related diseases, especially type 2 diabetes. Instead of broadly targeting all senescent cells, future therapies could focus on selectively removing or neutralizing only the harmful types, while preserving those that are still functional or even beneficial.

---

Source: link to paper